Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Shire PLC    SHP   JE00B2QKY057

SHIRE PLC (SHP)

Delayed Quote. Delayed  - 05/23 05:35:12 pm
4710 GBp   -2.35%
05/23 SHIRE : Blocklisting - Interim Review
05/19 SHIRE : What the other papers say this morning
05/18 SHIRE PLC (NASD : SHPG) Files An 8-K Other Events
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Shire : Files 8K - Other Events

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/17/2017 | 07:24pm CEST

Shire PLC (SHPG) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on February 17, 2017.

Shire plc has issued the press release attached hereto as Exhibit 99.1 which is incorporated by reference herein.

The full text of this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/936402/000095010317001531/dp73113_8k.htm

Any exhibits and associated documents for this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/936402/000095010317001531/0000950103-17-001531-index.htm

Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SHIRE PLC
05/23 SHIRE PLC : Financial Statements and Exhibits (form 8-K)
05/23 SHIRE : Blocklisting - Interim Review
05/19 SHIRE PLC : Blog Coverage: Shire's Stock Price Jumped on Positive Results in Her..
05/19 SHIRE : What the other papers say this morning
05/18 SHIRE PLC (NASDAQ : SHPG) Files An 8-K Other Events
05/18 SHIRE PLC : Financial Statements and Exhibits (form 8-K)
05/18 SHIRE : The Lancet Publishes Phase 2 Results from Shire’s Investigational ..
05/18DJSHIRE : Reports Positive Data For Angiodema Drug
05/18 SHIRE : Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Mont..
05/18 SHIRE : Positive lanadelumab topline Phase 3 results
More news
Sector news : Pharmaceuticals - NEC
05/23DJMERCK : FDA OKs Merck's Keytruda to Treat Cancers With Genetic Defects -- Update
05/23DJMERCK : FDA Approves Merck's Keytruda to Treat Cancers With Genetic Defects
05/23DJALEXION PHARMACEUTICALS : Shakeup Continues as Four Executives Exit -- 2nd Updat..
05/23DJALEXION PHARMACEUTICALS : Shakeup Continues as Four Executives Exit -- Update
05/23DJALEXION PHARMACEUTICALS : Management Shakeup Continues as Four More Executives E..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
05/23 SHIRE (SHPG) : Positive Topline Phase 3 Results for Lanadelumab (SHP643) in Pati..
05/23 Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2017 Update
05/22 Shire Is Poised To Dominate The HAE Market After Strong Phase III Data For SH..
05/22 Shire's long-acting hemophilia A candidate SHP656 fails to demonstrate treatm..
05/22 Tracking Tweedy Browne Portfolio - Q1 2017 Update
Advertisement
Financials ($)
Sales 2017 15 193 M
EBIT 2017 5 799 M
Net income 2017 2 736 M
Debt 2017 18 729 M
Yield 2017 0,60%
P/E ratio 2017 19,32
P/E ratio 2018 14,22
EV / Sales 2017 4,99x
EV / Sales 2018 4,39x
Capitalization 57 031 M
More Financials
Chart SHIRE PLC
Duration : Period :
Shire PLC Technical Analysis Chart | SHP | JE00B2QKY057 | 4-Traders
Full-screen chart
Technical analysis trends SHIRE PLC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 73,5 $
Spread / Average Target 17%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Flemming Ornskov Chief Executive Officer & Executive Director
Susan Saltzbart Kilsby Non-Executive Chairman
Jeffrey Poulton Chief Financial Officer & Executive Director
Philip J. Vickers Global Head-Research & Development
Matt Walker Head-Technical Operations
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SHIRE PLC3.59%57 031
JOHNSON & JOHNSON10.46%342 817
ROCHE HOLDING LTD.14.79%237 610
NOVARTIS AG6.28%213 719
PFIZER INC.-1.05%191 279
MERCK & CO., INC.9.65%175 160
More Results